Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BPTF | Q12830 | 17/20 | 1.00 |
| ▸ | KAT2B | Q92831 | 8/20 | 0.74 |
| ▸ | BRD9 | Q9H8M2 | 6/20 | 0.74 |
| ▸ | BRD4 | O60885 | 5/20 | 0.74 |
| ▸ | KAT2A | Q92830 | 1/20 | 0.74 |
| ▸ | CECR2 | Q9BXF3 | 1/20 | 0.74 |
| ▸ | BRD7 | Q9NPI1 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26910162 | 0.85 | BPTF (1.00) | BPTFKAT2BBRD9BRD4KAT2A | |
| SCHEMBL26910158 | 0.85 | BPTF (1.00) | BPTFKAT2BBRD9BRD4KAT2A | |
| SCHEMBL23682831 | 0.85 | BPTF (1.00) | BPTFKAT2BBRD9BRD4KAT2A | |
| SCHEMBL26910173 | 0.85 | BPTF (1.00) | BPTFKAT2BBRD9BRD4KAT2A | |
| SCHEMBL26910150 | 0.80 | BPTF (1.00) | BPTFKAT2BBRD9BRD4KAT2A | |
| SCHEMBL31735411 | 0.78 | BPTF (0.64) | BPTFKAT2BBRD9BRD4KAT2A | |
| SCHEMBL26910183 | 0.78 | BPTF (1.00) | BPTFKAT2BBRD9BRD4KAT2A | |
| SCHEMBL26910154 | 0.77 | BPTF (1.00) | BPTFKAT2BBRD9BRD4KAT2A | |
| SCHEMBL31735413 | 0.76 | BPTF (0.95) | BPTFKAT2BBRD9BRD4KAT2A | |
| SCHEMBL26910192 | 0.76 | BPTF (1.00) | BPTFKAT2BBRD9BRD4KAT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230391730-A1 | INHIBITORS OF THE BROMODOMAIN PHD FINGER TRANSCRIPTION FACTOR (BPTF) AS ANTI-CANCER AGENTS | REGENTS OF THE UNIVERSITY OF MINNESOTA | 2023-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230391730-A1 | INHIBITORS OF THE BROMODOMAIN PHD FINGER TRANSCRIPTION FACTOR (BPTF) AS ANTI-CANCER AGENTS | BPTF, BRPF3, PHF6 | BPTF 1/4885KAT2B 312/4885BRD9 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.